Furthermore, studies suggest that DPP4 may act as a tumor suppressor gene in the AR pathway, and its inhibition could potentially accelerate prostate cancer progression, particularly after androgen deprivation therapy. This evidence concerns the gene DPP4 and prostate carcinoma.